It Seems RepliCel Life Sciences Inc Will Go Up. Have Another Big Increase

 It Seems RepliCel Life Sciences Inc Will Go Up. Have Another Big Increase

The stock of RepliCel Life Sciences Inc (CVE:RP) is a huge mover today! About 26,106 shares traded hands or 6.90% up from the average. RepliCel Life Sciences Inc (CVE:RP) has risen 6.00% since October 5, 2016 and is uptrending. It has outperformed by 4.91% the S&P500.
The move comes after 7 months positive chart setup for the $6.26 million company. It was reported on Nov, 4 by We have $1.69 PT which if reached, will make CVE:RP worth $4.88 million more.

More important recent RepliCel Life Sciences Inc (CVE:RP) news were published by: which released: “RepliCel Life Sciences Share Consolidation Approved” on August 09, 2016, also published article titled: “RepliCel Life Sciences Amends Terms of Private Placement”, published: “RepliCel Life Sciences Announces Completion of the Final Injection in Its …” on August 11, 2016. More interesting news about RepliCel Life Sciences Inc (CVE:RP) was released by: and their article: “RepliCel Life Sciences Announces Closing of Private Placement” with publication date: October 31, 2016.

RepliCel Life Sciences Inc. is a regenerative medicine firm focused on developing autologous cell therapies that treat functional cellular deficits. The company has a market cap of $6.26 million. The Company’s product pipeline includes RCT-01-Tendon Repair, RCS-01-Skin Rejuvenation, RCH-01-Hair Regeneration and RCI-02-Dermal Injector. It currently has negative earnings. RCT-01 is an autologous cell treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle sheath to treat chronic tendinosis caused by acute and chronic tensile overuse.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment